Effect of rifaximin in patients with severe cirrhosis and ascites: A randomized double-blind placebo-controlled trial

Thévenot, Thierry; Thévenot, Thierry; Elkrief, Laure; Bureau, Christophe; Bardou‐Jacquet, Edouard; Rosa, Isabelle; Nguyen-Khac, Éric; Oberti, F.; Pitta, Anais; Mallet, Maxime; Lebossé, Fanny; Louvet, Alexandre; Meunier, Lucy; Nahon, Pierre; Ollivier‐Hourmand, Isabelle; Anty, Rodolphe; Francoz, Claire; Riachi, Ghassan; Meunier, Alexandre; Cervoni, Jean-Paul; Tio, Grégory; Muller, Allison; Curé-Martin, Audace; Ladeira, Ruben; Clairet, Anne‐Laure; Hocquet, Didier; Di Martino, Vincent; Weil, Delphine; Desmarets, Maxime

doi:10.1016/j.jhep.2025.06.019

Public

Effect of rifaximin in patients with severe cirrhosis and ascites: A randomized double-blind placebo-controlled trial

Published in Journal of Hepatology • Jul 15, 2025

Authors:

Thierry Thévenot

Laure Elkrief

Abstract

BACKGROUND & AIMS: Evidence supporting primary prophylaxis of spontaneous bacterial peritonitis (SBP) is weak and the selection of quinolone-resistant bacteria is a concern. Herein, we present results from a randomized, double-blind, placebo (PBO)-controlled trial to assess whether rifaximin (RFX) h...

Subject

Medicine

Spontaneous bacterial peritonitis

Ascites

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!